Matthew D. Galsky, MD, on How Data in Neoadjuvant Therapy May Inform Future Research Across Tumor Types

Video

CancerNetwork® spoke with Matthew D. Galsky, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss leading data to come out of the meeting and what it means for the future of cancer systemic therapy.

CancerNetwork® sat down with Matthew D. Galsky, MD, to discuss some of the data to come out of the American Association for Cancer Research (AACR) Annual Meeting 2021 that offer the greatest promise to the cancer treatment paradigm going forward. Interestingly, Galsky cited data regarding neoadjuvant therapy in the lung cancer setting as a promising indicator for future research in the genitourinary space.

Transcription:

One of the more interesting findings from a genitourinary oncologist’s standpoint is an observation from a lung cancer study that [looked at] neoadjuvant chemotherapy plus immune checkpoint blockade. [It showed] with the combination of immune checkpoint blockade plus chemotherapy a much higher pathologic complete response rate compared with chemotherapy alone. Again, that reinforces this concept of whether what we’re observing in metastatic urothelial cancer is a function of the chemotherapy backbone or that lung cancer and bladder cancer are just very different diseases, and we won’t see the same thing.

But the reason that the neoadjuvant lung cancer study is important to us in the field is that we have a number of ongoing neoadjuvant studies combining cisplatin-based chemotherapy with PD-1 or PD-L1 blockade for patients with muscle-invasive bladder cancer. If that is a hint of what we might see in bladder cancer as well, where the chemotherapy backbone in the neoadjuvant study is homogeneous and there isn’t this issue of carboplatin, hopefully we’ll see similar results in bladder cancer because we haven’t had new neoadjuvant chemotherapy regimens in this disease in decades.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content